Zimmer Biomet shares fell 13.5% after Q1 as investors reacted negatively to a cautious full-year outlook and evidence of ongoing revenue deceleration, despite in-line results for the quarter. The reaffirmed 2026 guidance of 1–3% organic growth—with continued pricing pressure and commercial transition disruptions—disappointed the market.

• Q1 organic sales grew 2.9% and U.S. sales rose 3.2%, but management reiterated full-year organic growth guidance at just 1–3%, implying deceleration ahead.
• Adjusted EPS for the quarter was $2.09, up 15% year-over-year, with a $0.20 benefit from favorable tariff actions.
• U.S. knee growth remained muted at 2.2%, with pressure from legacy product phase-outs; international knees grew just 1.3%.
• Management cited ongoing disruption from commercial transitions and maintained assumptions for up to 100 basis points of price erosion in 2026.
• Technology-driven segments like surgical and robotics posted near-12% growth, but these positives were overshadowed by continued challenges in restorative therapies and trauma.